Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 25 Issue 2, February 2007

Aspergillus niger, a fungus used for the production of enzymes and organic acids, on decaying Pelargonium petals. Pel et al. report the genome of this important bioindustrial fungus (p 221). Credit: Photo Researchers, Inc.

Editorial

  • The nonprofit Pew Initiative on Food and Biotechnology is closing, but the need for an independent and neutral body to facilitate dialog on US biotech policy has never been greater.

    Editorial

    Advertisement

  • A think tank and an investment bank have proposed solutions to address the lack of funding to carry biotech companies through the early stages of clinical development.

    Editorial
Top of page ⤴

News

Top of page ⤴

News in Brief

Top of page ⤴

News

  • When Merck KGaA purchased Geneva-based Serono in September, Actelion became Switzerland's largest biotech.

    • Charlie Schmidt
    News
Top of page ⤴

Data Page

Top of page ⤴

News Feature

  • Convergence products enable medical device companies to capture blockbuster markets. Opportunities exist but achievement is difficult.

    • Mark Ratner
    News Feature
Top of page ⤴

Correspondence

Top of page ⤴

Commentary

  • To reduce unacceptably high death rates from snakebite envenomation, sub-Saharan Africa must adopt not only a new generation of multivalent biotech antivenoms, but also an infrastructure to deliver them.

    • Roberto P Stock
    • Achille Massougbodji
    • Jean-Philippe Chippaux
    Commentary
Top of page ⤴

Book Review

Top of page ⤴

Feature

  • Five years after the US anthrax attacks, and more than two years after BioShield legislation was ratified, a survey reveals that biodefense funding has thus far produced only a handful of products for clinical development.

    • Melanie C Trull
    • Tracey V du Laney
    • Mark D Dibner
    Feature
Top of page ⤴

Patents

Top of page ⤴

News & Views

Top of page ⤴

Analysis

Top of page ⤴

Perspective

Top of page ⤴

Brief Communication

Top of page ⤴

Article

Top of page ⤴

Letter

Top of page ⤴

Erratum

Top of page ⤴

Corrigendum

Top of page ⤴

Careers and Recruitment

Top of page ⤴

People

Top of page ⤴

Search

Quick links